Cover Image
市場調查報告書

移植物抗宿主病 (GVHD):開發平台分析

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 234335
出版日期 內容資訊 英文 396 Pages
訂單完成後即時交付
價格
Back to Top
移植物抗宿主病 (GVHD):開發平台分析 Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 396 Pages
簡介

本報告提供移植物抗宿主病 (GVHD) 的治療方法之相關市場分析,提供您治療藥的開發·臨床實驗的最新趨勢,並彙整相關企業·組織簡介,開發中的產品,產業的最新趨勢等資訊。

簡介

  • 調查範圍

移植物抗宿主病 (GVHD) 概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

移植物抗宿主病 (GVHD):企業開發中的治療藥

移植物抗宿主病 (GVHD):大學/機關研究中的治療藥

移植物抗宿主病 (GVHD):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

移植物抗宿主病 (GVHD):企業開發中的產品

移植物抗宿主病 (GVHD):大學/機關研究中的產品

移植物抗宿主病 (GVHD) 的治療藥開發企業

  • AbbVie Inc.
  • AbGenomics International, Inc.
  • Actelion Ltd
  • Adienne Pharma & Biotech
  • Alexion Pharmaceuticals, Inc.
  • Apceth GmbH & Co. KG
  • Athersys, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bio-Cancer Treatment International Limited
  • Biogen, Inc.
  • Bristol-Myers Squibb Company
  • Caladrius Biosciences, Inc.
  • Cell2B S.A.
  • CytoDyn Inc.
  • Dr. Falk Pharma GmbH
  • Enlivex Therapeutics Ltd
  • Escape Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Generon (Shanghai) Corporation Ltd.
  • GlaxoSmithKline Plc
  • Idera Pharmaceuticals, Inc.
  • ImmuNext, Inc.
  • Immunomedics, Inc.
  • Jazz Pharmaceuticals Plc
  • Kadmon Corporation, LLC
  • Kamada Ltd.
  • Kiadis Pharma B.V.
  • Kymab Limited MacroGenics, Inc.
  • Mesoblast Limited
  • Millennium Pharmaceuticals, Inc.
  • MSM Protein Technologies, Inc.
  • Neopharm Ltd.
  • Novartis AG
  • Omni Bio Pharmaceutical Inc.
  • Pharmicell Co., Ltd.
  • R-Tech Ueno, Ltd.
  • reguimyun
  • Rigel Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.
  • Seattle Genetics, Inc.
  • Sigmoid Pharma Limited
  • Spherium Biomed S.L.
  • Targazyme, Inc.
  • Therapix Biosciences Ltd
  • Tobira Therapeutics, Inc.
  • Xenikos B.V.

移植物抗宿主病 (GVHD):治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abatacept
  • AbGn-168H
  • aldesleukin
  • Alecmestencel-L
  • Alpha-1 Antitrypsin
  • alpha-1 proteinase inhibitor (human)
  • ALXN-1007
  • anti-thymocyte globulin (rabbit)
  • Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD
  • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease
  • ApoCell
  • ATIR-101
  • BCT-100
  • begelomab
  • Biologics for Graft Versus Host Disease
  • bortezomib
  • BPX-501
  • brentuximab vedotin
  • budesonide
  • cannabidiol
  • Cell Therapy for Autoimmune Diseases and GVHD
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft versus Host Disease
  • Cell Therapy for Graft Versus Host Disease
  • Cell Therapy for Graft Versus Host Disease and Multiple Myeloma
  • cenicriviroc mesylate
  • CLBS-03
  • CRCBT-080004
  • cyclosporine IR + cyclosporine CR
  • CYP-001
  • defibrotide
  • Drugs for Acute and Chronic GVHD
  • erismodegib
  • F-652
  • Fc-Alpha-1 Antitrypsin
  • FcAAT-2
  • FcAAT-3
  • Ha-7
  • ibrutinib
  • ImmuneSafe
  • Immunocellgram for Graft Versus Host Disease
  • IMO-8400
  • inolimomab
  • IT-603
  • IT-901
  • KD-025
  • KY-1005
  • MesoStem
  • MGD-010
  • milatuzumab
  • Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases
  • MSM-707
  • MultiStem
  • natalizumab
  • Oligonucleotide to Inhibit NFAT1 for GVHD
  • panobinostat
  • ponesimod
  • Preimplantation Factor
  • PRO-140
  • Protein to Activate Toll-Like Receptor 5 for Infectious Disease and Graft Versus Host Disease
  • Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders
  • Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis
  • Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease
  • remestemcel-L
  • RGI-2001
  • RO-2959
  • RTU-009
  • Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders
  • Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorders
  • Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia
  • Small Molecules to Inhibit SHIP1 for Oncology and Immunology
  • SP-12008
  • Substance X
  • T-Guard
  • TZ-101

移植物抗宿主病 (GVHD):最近的開發平台趨勢

移植物抗宿主病 (GVHD):暫停中的計劃

移植物抗宿主病 (GVHD):開發中止的產品

移植物抗宿主病 (GVHD):產品開發的里程碑

  • 主要消息和新聞稿 (全10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8464IDB

Summary

Global Markets Direct's, 'Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2016', provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)
  • The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects
  • The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Graft Versus Host Disease (GVHD) Overview
  • Therapeutics Development
    • Pipeline Products for Graft Versus Host Disease (GVHD) - Overview
    • Pipeline Products for Graft Versus Host Disease (GVHD) - Comparative Analysis
  • Graft Versus Host Disease (GVHD) - Therapeutics under Development by Companies
  • Graft Versus Host Disease (GVHD) - Therapeutics under Investigation by Universities/Institutes
  • Graft Versus Host Disease (GVHD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Graft Versus Host Disease (GVHD) - Products under Development by Companies
  • Graft Versus Host Disease (GVHD) - Products under Investigation by Universities/Institutes
  • Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • AbGenomics International, Inc.
    • Actelion Ltd
    • Alexion Pharmaceuticals Inc
    • Amunix Operating Inc.
    • Apceth GmbH & Co. KG
    • arGEN-X BV
    • Athersys, Inc.
    • Bellicum Pharmaceuticals, Inc.
    • Bio-Cancer Treatment International Limited
    • Biogen Inc
    • Bristol-Myers Squibb Company
    • Cantex Pharmaceuticals, Inc.
    • Capricor Therapeutics, Inc.
    • Cell2B S.A.
    • CellECT Bio, Inc.
    • Cynata Therapeutics Limited
    • Cytodyn Inc.
    • Dompe Farmaceutici S.p.A.
    • Dr. Falk Pharma GmbH
    • Escape Therapeutics, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fate Therapeutics, Inc.
    • Generon (Shanghai) Corporation Ltd.
    • Gilead Sciences, Inc.
    • GlaxoSmithKline Plc
    • Idera Pharmaceuticals, Inc.
    • ImmuNext, Inc.
    • Immunomedics, Inc.
    • Incyte Corporation
    • Kadmon Corporation, LLC
    • Kamada Ltd.
    • Kiadis Pharma N.V.
    • Kymab Limited
    • Kyorin Pharmaceutical Co., Ltd.
    • MacroGenics, Inc.
    • Mallinckrodt Plc
    • Medsenic
    • Mesoblast Limited
    • Millennium Pharmaceuticals Inc
    • Neopharm Ltd.
    • Nohla Therapeutics Inc.
    • Novartis AG
    • OncoImmune, Inc.
    • OSE Immunotherapeutics
    • Pharmicell Co., Ltd.
    • REGiMMUNE Corporation
    • Rigel Pharmaceuticals, Inc.
    • Sarepta Therapeutics, Inc.
    • Seattle Genetics, Inc.
    • Seres Therapeutics, Inc.
    • Sigmoid Pharma Limited
    • Spherium Biomed S.L.
    • Takeda Pharmaceutical Company Limited
    • Targazyme, Inc.
    • Therapix Biosciences Ltd.
    • Tobira Therapeutics, Inc.
    • Vault Pharma Inc.
    • Xenikos B.V.
    • ZIOPHARM Oncology, Inc.
  • Graft Versus Host Disease (GVHD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abatacept - Drug Profile
    • AbGn-168H - Drug Profile
    • AGS-499 - Drug Profile
    • aldesleukin - Drug Profile
    • Alecmestencel-L - Drug Profile
    • alpha-1 proteinase inhibitor (human) - Drug Profile
    • ALXN-1007 - Drug Profile
    • AMX-342 - Drug Profile
    • anti-thymocyte globulin (rabbit) - Drug Profile
    • Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile
    • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile
    • ARGX-115 - Drug Profile
    • arsenic trioxide - Drug Profile
    • ATIR-101 - Drug Profile
    • BCT-200 - Drug Profile
    • begelomab - Drug Profile
    • Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile
    • Biologics for Graft Versus Host Disease - Drug Profile
    • bortezomib - Drug Profile
    • BPX-501 - Drug Profile
    • brentuximab vedotin - Drug Profile
    • budesonide - Drug Profile
    • cannabidiol - Drug Profile
    • CAP-2003 - Drug Profile
    • CD-24Fc - Drug Profile
    • Cell Therapy for Graft Versus Host Disease - Drug Profile
    • Cell Therapy for Graft-Versus Host Disease - Drug Profile
    • Cellgram for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile
    • Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile
    • cenicriviroc mesylate - Drug Profile
    • CRCBT-080004 - Drug Profile
    • CX-01 - Drug Profile
    • cyclosporine CR + cyclosporine IR - Drug Profile
    • CYP-001 - Drug Profile
    • entospletinib - Drug Profile
    • F-652 - Drug Profile
    • FR-104 - Drug Profile
    • Ha-7 - Drug Profile
    • ibrutinib - Drug Profile
    • ImmuneSafe - Drug Profile
    • ImmuStem - Drug Profile
    • IMO-8400 - Drug Profile
    • IT-603 - Drug Profile
    • IT-901 - Drug Profile
    • itacitinib adipate - Drug Profile
    • KD-025 - Drug Profile
    • KRP-203 - Drug Profile
    • KY-1005 - Drug Profile
    • MAX-16H5 - Drug Profile
    • MesoStem - Drug Profile
    • methoxsalen - Drug Profile
    • MGD-010 - Drug Profile
    • milatuzumab - Drug Profile
    • Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile
    • natalizumab - Drug Profile
    • nilotinib - Drug Profile
    • obinutuzumab - Drug Profile
    • OCU-300 - Drug Profile
    • Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile
    • panobinostat - Drug Profile
    • PF-05285401 - Drug Profile
    • ponesimod - Drug Profile
    • Preimplantation Factor - Drug Profile
    • PRO-140 - Drug Profile
    • ProTmune - Drug Profile
    • R-348 - Drug Profile
    • Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile
    • Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile
    • Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile
    • remestemcel-L - Drug Profile
    • reparixin - Drug Profile
    • RGI-2001 - Drug Profile
    • RO-2959 - Drug Profile
    • rovalpituzumab tesirine - Drug Profile
    • ruxolitinib phosphate - Drug Profile
    • S-Graft - Drug Profile
    • SER-155 - Drug Profile
    • Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile
    • Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile
    • Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile
    • Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile
    • sonidegib phosphate - Drug Profile
    • SP-12008 - Drug Profile
    • SYGN-305 - Drug Profile
    • Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile
    • T-Guard - Drug Profile
    • TZ-101 - Drug Profile
    • vedolizumab - Drug Profile
    • VPI-101 - Drug Profile
    • ZL-1101 - Drug Profile
  • Graft Versus Host Disease (GVHD) - Dormant Projects
  • Graft Versus Host Disease (GVHD) - Discontinued Products
  • Graft Versus Host Disease (GVHD) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016
  • Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Actelion Ltd, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Amunix Operating Inc. , H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Apceth GmbH & Co. KG, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by arGEN-X BV, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Athersys, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Bio-Cancer Treatment International Limited, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Cell2B S.A. , H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by CellECT Bio, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Limited, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Cytodyn Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Escape Therapeutics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by ImmuNext, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Immunomedics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corporation, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Corporation, LLC, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Kamada Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Kiadis Pharma N.V., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Kymab Limited, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by MacroGenics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Medsenic, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Limited, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Neopharm Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Nohla Therapeutics Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Novartis AG, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by OncoImmune, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Pharmicell Co., Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corporation, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Sarepta Therapeutics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Seattle Genetics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Spherium Biomed S.L., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Targazyme, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Tobira Therapeutics, Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by Xenikos B.V., H2 2016
  • Graft Versus Host Disease (GVHD) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Graft Versus Host Disease (GVHD) - Dormant Projects, H2 2016
  • Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..1), H2 2016
  • Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..2), H2 2016
  • Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..3), H2 2016
  • Graft Versus Host Disease (GVHD) - Dormant Projects (Contd..4), H2 2016
  • Graft Versus Host Disease (GVHD) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016
  • Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top